C-reactive protein lowering with rosuvastatin in the METEOR study

Area of Science:

• Cardiovascular disease prevention
• Pharmacology and therapeutics
• Inflammation biomarkers

Background:

• Statins, including rosuvastatin, are known to lower LDL-C and C-reactive protein (CRP).
• Long-term data on statin-induced CRP reduction in low-risk populations are limited.
• The independence of statin's CRP-lowering effect from LDL-C reduction requires further investigation.

Purpose of the Study:

• To evaluate the long-term effect of rosuvastatin on CRP levels in a low-risk population.
• To determine if rosuvastatin's reduction in CRP is independent of its LDL-C-lowering efficacy.
• To assess these effects within the context of the METEOR study.

Main Methods:

• A randomized, placebo-controlled trial (METEOR study) involving 984 low-risk subjects.
• Participants received 40 mg of rosuvastatin or a placebo for 2 years.
• Carotid intima media thickness (CIMT) was the primary endpoint; CRP levels were measured at baseline and after 2 years.

Main Results:

• Rosuvastatin treatment resulted in a significant 36% reduction in CRP levels compared to placebo.
• No correlation was observed between the change in CRP and the change in LDL-C (Spearman correlation: 0.08).
• The CRP-lowering effect was consistent across various baseline characteristics, with a greater magnitude in women and older participants.

Conclusions:

• Rosuvastatin (40 mg) effectively lowers CRP levels in low-risk individuals with normal baseline CRP and modest CIMT.
• The observed CRP reduction is independent of rosuvastatin's effects on LDL-C.
• These findings highlight a potential anti-inflammatory benefit of rosuvastatin beyond lipid modification.